Clinical observation of sitagliptin combined with metformin on patients with newly diagnosed type 2 diabetes

WU Hua; CHEN Min; SHAO Li-xiang; LIAO Ai-jiao; LI Xiao-li; LI Wei-ping; XIE Nai-qiang

doi:10.3760/cma.j.issn.1673-4777.2013.S1.010

Abstract：Objective To observe clinical efficacy of sitagliptin phosphate combined with metformin for patients with newly diagnosed type 2 diabetes.Methods All 85 patients with newly diagnosed type 2 diabetes,were divided into sitagliptin group (46 cases)and metformin group(39 cases).The patients in sitagliptin group were treated with sitagliptin(100 mg),and the patients in metformin group were treated with mefformin (500 mg,3 times per day) for 12 weeks.After 12 weeks,all patients were treated with a combination drag therapy for 12 weeks.The fasting blood glucose (FBG),2-hour postprandial blood glucose (2 h BG),glycated hemoglobin (HbA1c),lipids (TG,TC,LDL-C,HDL-C),insulin resistance index (HOMA-IR),and body mass index (BMI) were detected.Results The FBG,2 h BG,HOMA-IR and HbA1c in sitagliptin group and metformin group after treatment for 12 weeks were lower than those before treatment [sitagliptin group:(7.4 ± 1.2) mmol/L vs (9.6 ± 2.4) mmol/L,(9.0 ± 1.4)mmoL/L vs(13.2 ±3.4) mmol/L,(3.2 ±0.5) vs(6.2 ±0.5),(7.1 ±1.1)％ vs(8.7 ±2.5)％ ;mefformin group:(7.3 ±1.1)mmol/L vs(9.5 ±2.5) mmol/L,(8.9 ± 1.5)mmol/L vs(13.6 ±3.2) mmol/L,(3.3 ±0.4)vs (6.0 ± 0.7),(6.7 ± 1.2) ％ vs (8.6 ± 2.6) ％ ; P ＜ 0.05].Mter treatment with sitagliptin combined with metformin for 12 weeks,the FBG,2 h BG,HOMA-IR and HbA1c were(6.7 ± 1.1) mmol/L,(8.1 ± 1.2) mmol/L,(2.3 ± 0.3),(6.3 ± 1.3) ％,respectively,and obvious lower than those post-treatment in sitagliptin group and mefformin group(P ＜ 0.05 or P ＜ 0.01).Conclusion For patients with new diagnosed type 2 diabetes,sitagliptin combined with metformin can decrease the blood glucose,and possess good value in clinic.